Literature DB >> 18223674

Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention?

R C Chambers1.   

Abstract

There is compelling evidence that uncontrolled activation of the coagulation cascade following lung injury contributes to the development of lung inflammation and fibrosis in acute lung injury/acute respiratory distress syndrome (ALI/ARDS) and fibrotic lung disease. This article reviews our current understanding of the mechanisms leading to the activation of the coagulation cascade in response to lung injury and the evidence that excessive procoagulant activity is of pathophysiological significance in these disease settings. Current evidence suggests that the tissue factor-dependent extrinsic pathway is the predominant mechanism by which the coagulation cascade is locally activated in the lungs of patients with ALI/ARDS and pulmonary fibrosis. Whilst, fibrin deposition might contribute to the pathophysiology of ALI/ARDS following systemic insult; current evidence suggests that the cellular effects mediated via activation of proteinase-activated receptors (PARs) may be of particular importance in influencing inflammatory and fibroproliferative responses in experimental models involving direct injury to the lung. In this regard, studies in PAR(1) knockout mice have shown that this receptor plays a major role in orchestrating the interplay between coagulation, inflammation and lung fibrosis. This review will focus on our current understanding of excessive procoagulant signalling in acute and chronic lung injury and will highlight the novel opportunities that this may present for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18223674      PMCID: PMC2268072          DOI: 10.1038/sj.bjp.0707603

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  83 in total

Review 1.  Protease-activated receptors in hemostasis, thrombosis and vascular biology.

Authors:  S R Coughlin
Journal:  J Thromb Haemost       Date:  2005-08       Impact factor: 5.824

2.  Roles of protease-activated receptors in a mouse model of endotoxemia.

Authors:  Eric Camerer; Ivo Cornelissen; Hiroshi Kataoka; Daniel N Duong; Yao-Wu Zheng; Shaun R Coughlin
Journal:  Blood       Date:  2006-01-24       Impact factor: 22.113

Review 3.  Agonists and antagonists of protease activated receptors (PARs).

Authors:  Grant D Barry; Giang T Le; David P Fairlie
Journal:  Curr Med Chem       Date:  2006       Impact factor: 4.530

4.  Protease-activated receptor-2 activation induces acute lung inflammation by neuropeptide-dependent mechanisms.

Authors:  Xiao Su; Eric Camerer; Justin R Hamilton; Shaun R Coughlin; Michael A Matthay
Journal:  J Immunol       Date:  2005-08-15       Impact factor: 5.422

5.  Thrombin-activatable fibrinolysis inhibitor deficiency attenuates bleomycin-induced lung fibrosis.

Authors:  Hajime Fujimoto; Esteban C Gabazza; Osamu Taguchi; Yoichi Nishii; Hiroki Nakahara; Nelson E Bruno; Corina N D'Alessandro-Gabazza; Michael Kasper; Yutaka Yano; Mariko Nagashima; John Morser; George J Broze; Koji Suzuki; Yukihiko Adachi
Journal:  Am J Pathol       Date:  2006-04       Impact factor: 4.307

6.  Intratracheal gene transfer of tissue factor pathway inhibitor attenuates pulmonary fibrosis.

Authors:  Naoki Kijiyama; Hikaru Ueno; Isamu Sugimoto; Yasuyuki Sasaguri; Kazuhiro Yatera; Masamitsu Kido; Esteban C Gabazza; Koji Suzuki; Eikichi Hashimoto; Hiroyuki Takeya
Journal:  Biochem Biophys Res Commun       Date:  2005-12-05       Impact factor: 3.575

7.  Anticoagulant therapy for idiopathic pulmonary fibrosis.

Authors:  Hiroshi Kubo; Katsutoshi Nakayama; Masaru Yanai; Tomoko Suzuki; Mutsuo Yamaya; Mika Watanabe; Hidetada Sasaki
Journal:  Chest       Date:  2005-09       Impact factor: 9.410

8.  The SERPINE2 gene is associated with chronic obstructive pulmonary disease.

Authors:  Dawn L Demeo; Thomas J Mariani; Christoph Lange; Sorachai Srisuma; Augusto A Litonjua; Juan C Celedon; Stephen L Lake; John J Reilly; Harold A Chapman; Brigham H Mecham; Kathleen J Haley; Jody S Sylvia; David Sparrow; Avrum E Spira; Jennifer Beane; Victor Pinto-Plata; Frank E Speizer; Steven D Shapiro; Scott T Weiss; Edwin K Silverman
Journal:  Am J Hum Genet       Date:  2005-12-15       Impact factor: 11.025

9.  Individual domains of connective tissue growth factor regulate fibroblast proliferation and myofibroblast differentiation.

Authors:  Gary R Grotendorst; Matthew R Duncan
Journal:  FASEB J       Date:  2005-05       Impact factor: 5.191

10.  Proteinase-activated receptor-1 mediates elastase-induced apoptosis of human lung epithelial cells.

Authors:  Tomoko Suzuki; Theo J Moraes; Eric Vachon; Hedy H Ginzberg; Tsun-Tsao Huang; Michael A Matthay; Morley D Hollenberg; John Marshall; Christopher A G McCulloch; Maria Teresa Herrera Abreu; Chung-Wai Chow; Gregory P Downey
Journal:  Am J Respir Cell Mol Biol       Date:  2005-05-12       Impact factor: 6.914

View more
  59 in total

Review 1.  Mechanisms of fibrosis: therapeutic translation for fibrotic disease.

Authors:  Thomas A Wynn; Thirumalai R Ramalingam
Journal:  Nat Med       Date:  2012-07-06       Impact factor: 53.440

2.  Protease-activated receptor-2 induces myofibroblast differentiation and tissue factor up-regulation during bleomycin-induced lung injury: potential role in pulmonary fibrosis.

Authors:  Keren Borensztajn; Paul Bresser; Chris van der Loos; Ilze Bot; Bernt van den Blink; Michael A den Bakker; Joost Daalhuisen; Angelique P Groot; Maikel P Peppelenbosch; Jan H von der Thüsen; C Arnold Spek
Journal:  Am J Pathol       Date:  2010-10-22       Impact factor: 4.307

3.  Serum analysis of coagulation factors in IPF and NSIP.

Authors:  E Bargagli; C Madioni; N Bianchi; R M Refini; R Cappelli; P Rottoli
Journal:  Inflammation       Date:  2014-02       Impact factor: 4.092

4.  Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts.

Authors:  Galina S Bogatkevich; Anna Ludwicka-Bradley; Richard M Silver
Journal:  Arthritis Rheum       Date:  2009-11

Review 5.  Promising new treatment targets in patients with fibrosing lung disorders.

Authors:  Martina Sterclova; Martina Vasakova
Journal:  World J Clin Cases       Date:  2014-11-16       Impact factor: 1.337

6.  Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease.

Authors:  D B Sprunger; A L Olson; T J Huie; E R Fernandez-Perez; A Fischer; J J Solomon; K K Brown; J J Swigris
Journal:  Eur Respir J       Date:  2011-07-07       Impact factor: 16.671

7.  Epithelial responses to lung injury: role of the extracellular matrix.

Authors:  Harold A Chapman
Journal:  Proc Am Thorac Soc       Date:  2012-07

8.  Rationale for anticoagulant therapy of pulmonary fibrosis.

Authors:  Galina S Bogatkevich; Paul J Nietert; Richard M Silver; Kristin B Highland
Journal:  Am J Respir Crit Care Med       Date:  2014-02-01       Impact factor: 21.405

Review 9.  Recent advances in understanding the pathogenesis of scleroderma-interstitial lung disease.

Authors:  Tanjina Akter; Richard M Silver; Galina S Bogatkevich
Journal:  Curr Rheumatol Rep       Date:  2014-04       Impact factor: 4.592

10.  Low molecular weight heparin prevents CLP-induced acute lung injury in rats by anti-inflammatory coagulation.

Authors:  Xiao Lu; Liang Zhao; Yong-Hua Xu
Journal:  Bosn J Basic Med Sci       Date:  2013-02       Impact factor: 3.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.